Hartford Financial Management’s Crescent Biopharma CBIO Stock Holding History

Hartford Financial Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-35	Closed	-$10.5K	–	407
2024 Q1	$10.5K	Hold	35	–	–	﹤0.01%	308
2023 Q4	$8.26K	Hold	35	–	–	﹤0.01%	318
2023 Q3	$5.25K	Hold	35	–	–	﹤0.01%	331
2023 Q2	$6.09K	Hold	35	–	–	﹤0.01%	309
2023 Q1	$4.41K	Hold	35	–	–	﹤0.01%	316
2022 Q4	$10.6K	Hold	35	–	–	﹤0.01%	277
2022 Q3	$2K	Hold	35	–	–	﹤0.01%	352
2022 Q2	$2K	Hold	35	–	–	﹤0.01%	358
2022 Q1	$4K	Hold	35	–	–	﹤0.01%	339
2021 Q4	$5K	Hold	35	–	–	﹤0.01%	321
2021 Q3	$8K	Hold	35	–	–	﹤0.01%	304
2021 Q2	$8K	Hold	35	–	–	﹤0.01%	308
2021 Q1	$11K	Hold	35	–	–	﹤0.01%	292
2020 Q4	$13K	Hold	35	–	–	﹤0.01%	269
2020 Q3	$11K	Hold	35	–	–	﹤0.01%	258
2020 Q2	$13K	Buy	+35	New	+$9.91K	﹤0.01%	251

Other funds holding CBIO

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hartford Financial Management's CBIO Position: Q2 2024 in Review

Hartford Financial Management sold out of Crescent Biopharma (CBIO) in Q2 2024, closing a stake of 35 shares — an estimated $10.5K sold.

Hartford Financial Management first reported a position in CBIO in Q2 2020 and held it in 16 quarters. The position peaked at $13K in Q4 2020. 35 funds tracked by Wall St. Rank hold CBIO as of Q2 2024.

Hartford Financial Management reported no remaining Crescent Biopharma position as of Q2 2024 after selling out during the quarter.
Hartford Financial Management sold 35 Crescent Biopharma shares in Q2 2024, an estimated $10.5K.
Hartford Financial Management first reported a position in Crescent Biopharma in Q2 2020 and held it in 16 quarters.
Hartford Financial Management's Crescent Biopharma position peaked at $13K in Q4 2020.
35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2024.

Based on Hartford Financial Management's 13F filing for Q2 2024, filed 9 Aug 2024.